Pretreatment Neutrophil-to-Lymphocyte Ratio Can Predict the Prognosis in Bladder Cancer Patients Who Receive Gemcitabine and Nedaplatin Therapy

Shinji Ohtake, Takashi Kawahara, Ryo Kasahara, Hiroki Ito, Kimito Osaka, Yusuke Hattori, Jun Ichi Teranishi, Kazuhide Makiyama, Nobuhiko Mizuno, Susumu Umemoto, Yasuhide Miyoshi, Noboru Nakaigawa, Hiroshi Miyamoto, Masahiro Yao, Hiroji Uemura

Research output: Contribution to journalArticle

Abstract

Introduction and Objectives. Neutrophil-to-lymphocyte ratio (NLR) has been suggested to be a simple marker of the systemic inflammatory response in critical care patients. We previously assessed the utility of NLR as a biomarker to predict tumor recurrence and cancer death in bladder cancer patients who underwent radical cystectomy. In this study, we evaluated the prognostic impact of NLR in bladder cancer patients who received gemcitabine and nedaplatin (GN) chemotherapy. Methods. A total of 23 patients who received GN chemotherapy for advanced bladder cancer were enrolled in this study. The cut-off point of NLR according to the sensitivity and specificity levels was derived from the area under receiver operator characteristics (AUROC) curve plotted for disease progression or overall mortality. Results. The NLR cut-off point was determined as 4.14 for both tumor progression and overall mortality. Median progression-free survival (PFS)/overall survival (OS) in the higher NLR group (NLR ≥ 4.14) and lower NLR group (NLR < 4.14) were 194/468 days versus 73/237 days, respectively. Kaplan-Meier analysis showed that higher NLR significantly correlated with poorer PFS (p = 0.011) and OS (p = 0.045). Conclusions. NLR may serve as a new biomarker to predict responses to GN-based chemotherapy in advanced bladder cancer patients and/or their prognosis.

Original languageEnglish (US)
Article number9846823
JournalBioMed Research International
Volume2016
DOIs
StatePublished - 2016

Fingerprint

gemcitabine
Lymphocytes
Urinary Bladder Neoplasms
Neutrophils
Chemotherapy
Therapeutics
Biomarkers
Drug Therapy
Disease-Free Survival
Tumors
nedaplatin
Neoplasms
Survival
Mortality
Cystectomy

ASJC Scopus subject areas

  • Immunology and Microbiology(all)
  • Biochemistry, Genetics and Molecular Biology(all)

Cite this

Pretreatment Neutrophil-to-Lymphocyte Ratio Can Predict the Prognosis in Bladder Cancer Patients Who Receive Gemcitabine and Nedaplatin Therapy. / Ohtake, Shinji; Kawahara, Takashi; Kasahara, Ryo; Ito, Hiroki; Osaka, Kimito; Hattori, Yusuke; Teranishi, Jun Ichi; Makiyama, Kazuhide; Mizuno, Nobuhiko; Umemoto, Susumu; Miyoshi, Yasuhide; Nakaigawa, Noboru; Miyamoto, Hiroshi; Yao, Masahiro; Uemura, Hiroji.

In: BioMed Research International, Vol. 2016, 9846823, 2016.

Research output: Contribution to journalArticle

Ohtake, S, Kawahara, T, Kasahara, R, Ito, H, Osaka, K, Hattori, Y, Teranishi, JI, Makiyama, K, Mizuno, N, Umemoto, S, Miyoshi, Y, Nakaigawa, N, Miyamoto, H, Yao, M & Uemura, H 2016, 'Pretreatment Neutrophil-to-Lymphocyte Ratio Can Predict the Prognosis in Bladder Cancer Patients Who Receive Gemcitabine and Nedaplatin Therapy', BioMed Research International, vol. 2016, 9846823. https://doi.org/10.1155/2016/9846823
Ohtake, Shinji ; Kawahara, Takashi ; Kasahara, Ryo ; Ito, Hiroki ; Osaka, Kimito ; Hattori, Yusuke ; Teranishi, Jun Ichi ; Makiyama, Kazuhide ; Mizuno, Nobuhiko ; Umemoto, Susumu ; Miyoshi, Yasuhide ; Nakaigawa, Noboru ; Miyamoto, Hiroshi ; Yao, Masahiro ; Uemura, Hiroji. / Pretreatment Neutrophil-to-Lymphocyte Ratio Can Predict the Prognosis in Bladder Cancer Patients Who Receive Gemcitabine and Nedaplatin Therapy. In: BioMed Research International. 2016 ; Vol. 2016.
@article{3016a989cf67446db39f8a4aa6cc0cd8,
title = "Pretreatment Neutrophil-to-Lymphocyte Ratio Can Predict the Prognosis in Bladder Cancer Patients Who Receive Gemcitabine and Nedaplatin Therapy",
abstract = "Introduction and Objectives. Neutrophil-to-lymphocyte ratio (NLR) has been suggested to be a simple marker of the systemic inflammatory response in critical care patients. We previously assessed the utility of NLR as a biomarker to predict tumor recurrence and cancer death in bladder cancer patients who underwent radical cystectomy. In this study, we evaluated the prognostic impact of NLR in bladder cancer patients who received gemcitabine and nedaplatin (GN) chemotherapy. Methods. A total of 23 patients who received GN chemotherapy for advanced bladder cancer were enrolled in this study. The cut-off point of NLR according to the sensitivity and specificity levels was derived from the area under receiver operator characteristics (AUROC) curve plotted for disease progression or overall mortality. Results. The NLR cut-off point was determined as 4.14 for both tumor progression and overall mortality. Median progression-free survival (PFS)/overall survival (OS) in the higher NLR group (NLR ≥ 4.14) and lower NLR group (NLR < 4.14) were 194/468 days versus 73/237 days, respectively. Kaplan-Meier analysis showed that higher NLR significantly correlated with poorer PFS (p = 0.011) and OS (p = 0.045). Conclusions. NLR may serve as a new biomarker to predict responses to GN-based chemotherapy in advanced bladder cancer patients and/or their prognosis.",
author = "Shinji Ohtake and Takashi Kawahara and Ryo Kasahara and Hiroki Ito and Kimito Osaka and Yusuke Hattori and Teranishi, {Jun Ichi} and Kazuhide Makiyama and Nobuhiko Mizuno and Susumu Umemoto and Yasuhide Miyoshi and Noboru Nakaigawa and Hiroshi Miyamoto and Masahiro Yao and Hiroji Uemura",
year = "2016",
doi = "10.1155/2016/9846823",
language = "English (US)",
volume = "2016",
journal = "BioMed Research International",
issn = "2314-6133",
publisher = "Hindawi Publishing Corporation",

}

TY - JOUR

T1 - Pretreatment Neutrophil-to-Lymphocyte Ratio Can Predict the Prognosis in Bladder Cancer Patients Who Receive Gemcitabine and Nedaplatin Therapy

AU - Ohtake, Shinji

AU - Kawahara, Takashi

AU - Kasahara, Ryo

AU - Ito, Hiroki

AU - Osaka, Kimito

AU - Hattori, Yusuke

AU - Teranishi, Jun Ichi

AU - Makiyama, Kazuhide

AU - Mizuno, Nobuhiko

AU - Umemoto, Susumu

AU - Miyoshi, Yasuhide

AU - Nakaigawa, Noboru

AU - Miyamoto, Hiroshi

AU - Yao, Masahiro

AU - Uemura, Hiroji

PY - 2016

Y1 - 2016

N2 - Introduction and Objectives. Neutrophil-to-lymphocyte ratio (NLR) has been suggested to be a simple marker of the systemic inflammatory response in critical care patients. We previously assessed the utility of NLR as a biomarker to predict tumor recurrence and cancer death in bladder cancer patients who underwent radical cystectomy. In this study, we evaluated the prognostic impact of NLR in bladder cancer patients who received gemcitabine and nedaplatin (GN) chemotherapy. Methods. A total of 23 patients who received GN chemotherapy for advanced bladder cancer were enrolled in this study. The cut-off point of NLR according to the sensitivity and specificity levels was derived from the area under receiver operator characteristics (AUROC) curve plotted for disease progression or overall mortality. Results. The NLR cut-off point was determined as 4.14 for both tumor progression and overall mortality. Median progression-free survival (PFS)/overall survival (OS) in the higher NLR group (NLR ≥ 4.14) and lower NLR group (NLR < 4.14) were 194/468 days versus 73/237 days, respectively. Kaplan-Meier analysis showed that higher NLR significantly correlated with poorer PFS (p = 0.011) and OS (p = 0.045). Conclusions. NLR may serve as a new biomarker to predict responses to GN-based chemotherapy in advanced bladder cancer patients and/or their prognosis.

AB - Introduction and Objectives. Neutrophil-to-lymphocyte ratio (NLR) has been suggested to be a simple marker of the systemic inflammatory response in critical care patients. We previously assessed the utility of NLR as a biomarker to predict tumor recurrence and cancer death in bladder cancer patients who underwent radical cystectomy. In this study, we evaluated the prognostic impact of NLR in bladder cancer patients who received gemcitabine and nedaplatin (GN) chemotherapy. Methods. A total of 23 patients who received GN chemotherapy for advanced bladder cancer were enrolled in this study. The cut-off point of NLR according to the sensitivity and specificity levels was derived from the area under receiver operator characteristics (AUROC) curve plotted for disease progression or overall mortality. Results. The NLR cut-off point was determined as 4.14 for both tumor progression and overall mortality. Median progression-free survival (PFS)/overall survival (OS) in the higher NLR group (NLR ≥ 4.14) and lower NLR group (NLR < 4.14) were 194/468 days versus 73/237 days, respectively. Kaplan-Meier analysis showed that higher NLR significantly correlated with poorer PFS (p = 0.011) and OS (p = 0.045). Conclusions. NLR may serve as a new biomarker to predict responses to GN-based chemotherapy in advanced bladder cancer patients and/or their prognosis.

UR - http://www.scopus.com/inward/record.url?scp=84994515489&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84994515489&partnerID=8YFLogxK

U2 - 10.1155/2016/9846823

DO - 10.1155/2016/9846823

M3 - Article

AN - SCOPUS:84994515489

VL - 2016

JO - BioMed Research International

JF - BioMed Research International

SN - 2314-6133

M1 - 9846823

ER -